PharmaSGP Holding SE

XTRA:PSG Stock Report

Market Cap: €299.8m

PharmaSGP Holding Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Natalie Weigand

Chief executive officer

€865.0k

Total compensation

CEO salary percentage34.7%
CEO tenure4.8yrs
CEO ownershipn/a
Management average tenure4.8yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

PharmaSGP Holding's (ETR:PSG) Performance Is Even Better Than Its Earnings Suggest

Dec 06
PharmaSGP Holding's (ETR:PSG) Performance Is Even Better Than Its Earnings Suggest

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

May 06
Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Mar 02
Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Dec 02
PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

Feb 16
One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Jan 26
We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Dec 04
Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

CEO Compensation Analysis

How has Natalie Weigand's remuneration changed compared to PharmaSGP Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

€19m

Jun 30 2024n/an/a

€18m

Mar 31 2024n/an/a

€18m

Dec 31 2023€865k€300k

€16m

Sep 30 2023n/an/a

€15m

Jun 30 2023n/an/a

€14m

Mar 31 2023n/an/a

€13m

Dec 31 2022€314k€250k

€12m

Sep 30 2022n/an/a

€11m

Jun 30 2022n/an/a

€11m

Mar 31 2022n/an/a

€11m

Dec 31 2021€272k€250k

€11m

Sep 30 2021n/an/a

€8m

Jun 30 2021n/an/a

€8m

Mar 31 2021n/an/a

€9m

Dec 31 2020€279k€258k

€11m

Sep 30 2020n/an/a

€16m

Jun 30 2020n/an/a

€17m

Mar 31 2020n/an/a

€17m

Dec 31 2019€141k€141k

€17m

Compensation vs Market: Natalie's total compensation ($USD907.18K) is about average for companies of similar size in the German market ($USD1.04M).

Compensation vs Earnings: Natalie's compensation has increased by more than 20% in the past year.

CEO

Natalie Weigand (43 yo)

4.8yrs

Tenure

€865,000

Compensation

Ms. Natalie Weigand serves as the Chief Executive Officer at PharmaSGP Holding SE since June 2020 and also serves as a Member of Management Board since March 04, 2020. She joined the FUTRUE Group as the le...

Leadership Team

NamePositionTenureCompensationOwnership
Natalie Weigand
CEO & Member of Management Board4.8yrs€865.00kno data
Michael Rudolf
CFO & Member of Management Board4.8yrs€879.00kno data
Peter Gerckens
Member of Management Boardless than a yearno datano data

4.8yrs

Average Tenure

Experienced Management: PSG's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Axel Rebien
Member of the Supervisory Board4.5yrs€50.00kno data
Madlena Hohlefelder
Deputy Chairwoman of the Supervisory Board4.8yrsno data48.95%
€ 146.7m
Clemens Fischer
Chairman of the Supervisory Board4.8yrsno datano data

4.8yrs

Average Tenure

49yo

Average Age

Experienced Board: PSG's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 17:10
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmaSGP Holding SE is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gerhard OrgonasBerenberg
Charles WestonRBC Capital Markets
Jack Reynolds-ClarkRBC Capital Markets